| INTRODUCTION
Tuberculosis (TB) is a global pandemic and was responsible for the death of 1.3 million HIV-negative patients and 374,000 HIV-positive people in the year 2016. Recent WHO report has highlighted that TB ranks alongside HIV/AIDS as the world's leading infectious disease killer, while shining a spotlight on progress made in several countries, including India. [1] The campaign to reduce TB infections is seriously jeopardized by multidrug-resistant tuberculosis(MDR-TB), extremely drugresistant tuberculosis (XDR-TB), and total drug-resistant (TDR) tuberculosis. [2] There is an urgent need to develop safe and effective drugs for the treatment of TB infection. Mycobacterium tuberculosis (MTb) synthesizes fatty acid via the type II pathway, which is absent in human beings. Enoyl-ACP reductase (ENR) is a key regulatory enzyme of the type II FAS pathway, and it catalyzes the final step of type II fatty acid elongation cycle. Inhibition of the fatty acid synthesis pathway is an attractive option since the drugs, which inhibit this pathway, can be selectively toxic to MTb. Triclosan (1) (Figure 1 ), a diphenyl ether derivative, targets mycobacterial ENR and exhibits MIC of 12.5 μg/ml against Mycobacterium tuberculosis H37Rv. [3] Unlike isoniazid (INH), triclosan does not require prior activation to bind with Mtb ENR. [4] From the literature reports on existing inhibitors of Mtb ENR, it can be proposed that blocking the entry of natural substrate (acyl carrier protein) by the inhibitors such as triclosan could be a plausible approach to disturb the essential reduction step in the mycobacterial mycolic acid biosynthesis. [5] Thus, the attempts to find diphenyl ether-based anti-TB agents have geared up
In our efforts to develop druggable diphenyl ethers as potential antitubercular agents, a series of novel diphenyl ether derivatives (5a-f, 6a-f) were designed and synthesized.
The representative compounds showed promising in vitro activity against drugsusceptible, isoniazid-resistant, and multidrug-resistant strains of Mycobacterium tuberculosis with MIC values of 1.56 μg/ml (6b), 6.25 μg/ml (6a-d), and 3.125 μg/ml (6b-c), respectively. All the synthesized compounds exhibited satisfactory safety profile (CC 50 > 300 μg/ml) against Vero and HepG2 cells. Reverse phase HPLC method was used to probe the physicochemical properties of the synthesized compounds. This series of compounds demonstrated comparatively low logP values. pKa values of representative compounds indicated that they were weak acids. Additionally, in vitro human liver microsomal stability assay confirmed that the synthesized compounds possessed acceptable stability under study conditions. The present study thus establishes compound 6b
as the most promising antitubercular agent with acceptable drug-likeness.
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antitubercular agents, diphenyl ether, human liver microsomal stability, physicochemical studies, safety profile in the recent past. [6] [7] [8] [9] Although triclosan carries the promise to combat resistant strains of mycobacterium, its utility for human treatment is limited due to its poor solubility and suboptimal bioavailability. [10] Hence, transforming triclosan into an efficient antitubercular agent is a major challenge. Encouraged with our previous experience with diphenyl ether scaffold [11, 12] and subsequent literature reports of antitubercular potential of related compounds, we decided to carry out further studies and develop novel diphenyl ether derivatives as potential antitubercular agents with improved druggability. Another purpose of this research work is to get relevant information on the structural requirement of diphenyl ether scaffold to improve its antitubercular potential.
| EXPERIMENTAL SECTION

| Methods and materials
All moisture-sensitive reactions were carried out under nitrogen atmosphere in anhydrous solvents. Column chromatography was carried out on 100-200 mesh silica gel. The progress of the reactions was monitored by TLC using aluminumbacked sheets of silica gel 60F24 (Merck). Melting points were recorded with a laboratory melting point apparatus and are uncorrected. C NMR spectra were recorded on a NMR Spectrometer (AV400-400 MHz High Resolution Multinuclear FT-NMR Spectrometer, Bruker) using DMSO-d 6 as the solvent. Mass spectrometry (MS) data were obtained on a LC-MS (Agilent 6520 series, Q-TOF LC/MS) and GC-MS (Shimadzu GC-17A, GC-MS-QP5050A). IR spectra were recorded on Shimadzu Affinity-1 FT IR spectrophotometer. UV-visible spectra were recorded on Shimadzu UV-2450 spectrophotometer, and λmax was recorded. The purity of the final compounds was checked by reverse phase HPLC (UFLC, Shimadzu) using C-18 column in isocratic mode solvent systems (methanol and buffer, pH = 7.4) and found to be ≥95%.
| Synthesis of 1-(3-methoxy-4-phenoxyphenyl) ethanone (2)
The 1-(3-methoxy-4-phenoxyphenyl) ethanone (2) was prepared as per the previously reported method [12] and purified by column chromatography over silica 100-200 with hexane: ethyl acetate (8:2) as the mobile phase.
| Synthesis of 1-(3-hydroxy-4-phenoxyphenyl) ethanone (3)
The 1-(3-hydroxy-4-phenoxyphenyl) ethanone (3) was prepared as per the previously reported method [12] and purified by column chromatography over silica 100-200 with hexane: ethyl acetate (6:4) as the mobile phase.
| General method for synthesis of 1-(3-hydroxy-4-phenoxyphenyl)-3-aryl prop-2-en-1-one (4a-f)
The 1-(3-hydroxy-4-phenoxyphenyl)-3-aryl prop-2-en-1-one (4a-f) was prepared as per the previously reported method [12] and purified by column chromatography over silica 100-200 with hexane: ethyl acetate (6:4) as the mobile phase.
| General method for synthesis of 1-(3-hydroxy-4-phenoxyphenyl)-3-aryl propan-1-one (5a-f)
To a solution of compounds 4a-f (2 mmol) in absolute alcohol (50 ml) and THF (10 ml) , 15 ml of saturated aqueous solution of NH4Cl (80 mmol) was added at 25-27°C. Then, the reaction mixture was added with Zn (12 mmol) in four portions at 10-minute interval and stirred for 6 hr at ambient temperature. The progress of the reaction was monitored by TLC, using hexane: ethyl acetate (8:2) as the mobile phase. After the completion of reaction (6 hr), the reaction mixture was filtered and the filtrate was evaporated under vacuum to remove the volatiles. The residue obtained was added with ice cold water and extracted with ethyl acetate (3 × 25 ml). The organic layers were separated, pooled, washed with water, brine, dried over anhydrous MgSO 4, and evaporated under vacuum. The crude compound was purified by column chromatography over silica 100-200 with hexane: ethyl acetate (8:2) as the mobile phase to afford the target compound.
| General method for synthesis of 5-(1-hydroxy-3-phenylpropyl)-2-phenoxyphenol (6a-f)
To the solution of compounds 1-(3-hydroxy-4-phenoxyph enyl)-3-aryl propan-1-one (5a-f) (0.75 mmol) in methanol (4 ml) and THF (2 ml), NaBH 4 (3.0 mmol) dissolved in aq. NaOH (4N, 1 ml) was added in three portions and stirred at ambient temperature. The progress of the reaction was monitored by TLC, using hexane: ethyl acetate (6:4) as the mobile phase. After the completion of reaction (2 hr), the reaction mixture was quenched with saturated NH 4 Cl solution (5 ml) and evaporated under vacuum to remove the volatiles. The residue obtained was added into ice cold water, neutralized to pH 7 (by adding dil. HCl), and extracted with ethyl acetate (3 × 25 ml). The organic layers were separated, pooled, washed with water, brine, dried over anhydrous MgSO 4, and evaporated under vacuum. The crude compound was purified by column chromatography over silica 100-200 with hexane: ethyl acetate (6:4) as the mobile phase to afford the target compound.
| In vitro antitubercular screening against drug-susceptible strains of Mycobacterium tuberculosis H37Rv and In vitro cell cytotoxicity screening
Procedure for MIC determination (microplate alamar blue assay) against drug-susceptible strains of Mycobacterium tuberculosis H37Rv has been reported previously. [12, 13] Methods for the determination of CC 50 (MTT assay) against Vero and HepG2 cells have been reported previously. [12, 14, 15] 
| In vitro antitubercular screening against drug-resistant strains of Mycobacterium tuberculosis
Selected compounds were screened against isoniazid-resistant and multidrug-resistant (MDR) strains of Mycobacterium tuberculosis H37Rv using mycobacterial growth indicator tube (MGIT) assay method. Isoniazid-resistant/multidrugresistant Mycobacterium tuberculosis strain (clinical isolates) suspension was prepared as per the literature method. [16] It was diluted to afford a turbidity of 0.5 McFarland standard. 1 ml of the adjusted suspension was diluted in 4 ml of sterile saline (1:5 dilution). About 0.1 ml of the isoniazid-resistant/ multidrug-resistant Mycobacterium tuberculosis (clinical isolates) strain suspension was added into 10 ml of sterile saline to prepare the 1:100 growth control suspension and mixed thoroughly. Test compounds were dissolved in DMSO and sterilized by filtering through syringe filters (0.22 μm) to prepare stock solutions of concentration 10,000 μg/ml. The stock solutions were diluted with saline water to afford working solutions of 80X strength. Isoniazid and rifampicin were used as standard. Mycobacterium Growth Indicator Tubes (BBL ™ MGIT ™ , 7 ml, BD Bioscience, catalog No. 245122), labeled with compound codes and concentrations, were added with 0.8 ml OADC, 0.1 ml test compounds, and 0.5 ml of mycobacterial strain. Growth control tubes contained only OADC and mycobacterial culture. Each test sample was added to four MGITs at different concentrations and placed in a tube holder with one growth control tube. Contents of tubes were mixed well. Then, the tubes were placed inside the BACTEC MGIT-900 instrument at 37°C for 14 days. The BACTEC MGIT-960 instrument monitored the fluorescence of the MGITs, and the results were reported. The results were analyzed by comparing the fluorescence of test sample tube and growth control tube. The MIC was defined as the lowest concentration of drug that inhibited bacterial growth.
| Determination of logP, pKa, and human liver microsomal stability assay
LogP, pKa, and human liver microsomal stability of the compounds 5a-f and 6a-f were determined by previously reported methods.
[12,17-18]a
| RESULTS AND DISCUSSION
| Design and chemistry
Phenolic-OH at 2nd position of the ring-A of triclosan (1, Figure 1 ) plays a crucial role in binding to the catalytic site of Mtb ENR. The presence of three chloro groups makes this compound highly lipophilic and nonselective to InhA. Sivaraman et al. reported that ring-B chloro substitutions in triclosan were involved in unfavorable steric interactions with the enzyme and their deletion from the scaffold increased the affinity sevenfold. [7] In addition to this, diphenyl ethers substituted with long alkyl chains at 4th position of ring-A have been reported to display better affinity toward Mtb ENR than triclosan. [6] But those compounds were highly lipophilic and showed low aqueous solubility. Hence, design of structurally similar diphenyl ether derivatives focused mainly on incorporating substituents at the 4th position and one -OH group at 2nd position of ring-A. α, β-unsaturated ketone was introduced at the 4th position of ring-A of diphenyl ether moiety, forecasting that it would mimic the reactivity of trans-2-enoyl acyl part of enoyl acyl carrier protein (Figure 1 ) at the catalytic site of Mtb ENR. Although the antitubercular activity of α, β-unsaturated ketones (chalcones) is already reported, their carcinogenicity and metabolic instability make them unsuitable for lead optimization. [19] Thus, the metabolically labile reactive conjugated system in the chalcones was modified to lesser reactive corresponding nonconjugated ketones and alcohols. Synthesis of this series of compounds is described in Scheme 1. Acetovanillone was taken as starting material and condensed with phenyl boronic acid by Chan-Lam Oarylation reaction. Obtained ketone (compound 2) was subjected to BBr 3 -assisted demethylation reaction as described by Gillmore et al. [20] The Claisen-Schmidt condensation reaction of compound 3 with different benzaldehydes afforded respective chalcones (compounds 4a-f). Selective reduction in conjugated double bond of compounds 4a-f was optimized using Zn/NH 4 Cl, where, Zn and NH 4 Cl provided electron and proton. [21] Due to the weak polarization, conjugated double bond of the chalcones was not affected by this mild reducing agent and corresponding dihydrochalcones (5a-f) were obtained with 63.70% yield. In order to increase the polar surface area, obtained dihydrochalcones (5a-f) were reduced further by NaBH 4 to give compounds 6a-f with 82.93% yield. Notably, NaBH 4 -assisted reduction in carbonyl group of compounds 5a-f to corresponding alcohols (6a-f) was observed to be fastened in the presence of alkali (NaOH). Spectral data of all the synthesized compounds are included in the supporting information.
| Biological evaluation
Compounds 5a-f and 6a-f were screened against Mycobacterium tuberculosis H37Rv. Their MIC results are given in Table 1 . Safety profile (CC 50 ) of this series of compounds was established from MTT assay against Vero and HepG2 cells (Table 1) . Antitubercular potential of diphenyl ether derivatives was improved upon extension of alkyl chain with bulky substituents at 4th position of ring-A. Alkyl substituents of dihydrochalcones bearing 4-F-Phenyl (5d) and furan ring (5f) demonstrated significant antitubercular activity (MIC 10 μg/ml). All dihydrochalcone derivatives (compounds 5a-f) showed acceptable safety profile against normal and human hepatoma cells (CC 50 >300 μg/ml). Dramatic improvement in anti-TB activity was observed when keto functionality of dihydrochalcones (5a-f) was reduced to corresponding racemic alcohol derivatives (6a-f). Interestingly, compounds 6a and 6c-f exhibited MIC of 4 μg/ml, and compounds 6b and 6c exhibited significant antitubercular activity with MIC of 1.56 and 3.125 μg/ml, respectively. In this case, electron-donating groups on phenyl substituent (6b-c) were observed to be more favorable for antitubercular activity. A closer comparison between the MIC of triclosan (MIC 12.5 μg/ml) and the compounds of the series shows that the presence of hydroxy substituent adjacent to ring-A is critical for improving the anti-TB activity. All the compounds of this series achieved adequate safety profile (CC 50 > 300 μg/ ml) against Vero and HepG2 cells and demonstrated selective index >10.
Most promising compounds 6a-f having MIC <10 μg/ ml against drug-susceptible strain of Mycobacterial tuberculosis H 37 Rv were selected for antitubercular screening 
| Physicochemical studies
In order to probe the lipophilicity, experimental logP of synthesized was determined by reverse phase HPLC method. In this method, the stationary phase simulated the biological lipophilic membrane, and retention of the compounds was correlated with its lipophilicity. Most of the synthesized compounds demonstrated moderate logP (Table 3) . In-depth analysis of logP of compounds indicated that there was no relationship between lipophilicity and observed antitubercular activity.
pKa of representative compounds was determined using reverse phase HPLC method. pKa was calculated from the retention factor (k′) and is shown in Table 3 . Compound 5b showed pKa 9.72. When the carbonyl group of 5b was replaced with an electron-donating secondary alcohol group in case of compounds 6b and 6e, the acidity of phenolic-OH was shot up and resulted in pKa 6-6.24. With increased acidity, compounds 6b (MIC 1.56 μg/ml) and 6e (MIC 4 μg/ml) showed substantial improvement in antitubercular activity. This may be due to the fact that compounds having pKa near to 6 are capable of producing optimum proportion of ionized and unionized species at biological pH (pH 7.4) to solubilize and penetrate the membrane of the mycobacterium. This observation was totally in agreement with the fact that the acidity of the drugs influenced their antitubercular activity. Human liver microsome (HLM) stability (%) of selected compounds with promising antitubercular activity was determined at different time-points (1 and 2 hr). The presence of a phenolic -OH group in triclosan moiety makes it susceptible for metabolism. [10] Hence, phenolic -OH present in our diphenyl ether derivatives is theoretically susceptible to HLMassisted metabolism. Nevertheless, in contrast to literature reports, HLM stability assay results (Table 3 ) of our synthesized compounds indicated that they were stable when incubated with human liver microsomes (retention >50% after 1 hr).
| CONCLUSIONS
In conclusion, novel diphenyl ether derivatives have been synthesized and evaluated for their in vitro antitubercular activity. 6b was identified as the most promising compound which exhibited MIC of 1.56, 6.25, and 3.125 μg/ml, respectively, against drug-susceptible, isoniazid-resistant, and multidrugresistant (MDR) strains of Mycobacterium tuberculosis. The safety profile of all synthesized compounds against Vero and HepG2 cells (CC 50 > 300 μg/ml) was satisfactory. In the present study, we were able to decrease the intrinsic lipophilicity of diphenyl ether scaffold to an acceptable limit with improved antitubercular potency against both drug-susceptible and drug-resistant strains. All the synthesized diphenyl ether derivatives showed acceptable metabolic stability (retention >50% after 1 hr) against human liver microsomes. The present study indicates that there is further scope to explore diphenyl ethers as antitubercular agents. To this end, work is in progress to do the Mtb ENR enzyme assay of promising compounds and to elucidate the mechanism of action on a molecular level.
